This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.
Women aged 18 to 75 years old (including both values).
ECOG Physical Strength Status (PS) : 0 to 1 point.
Patients with locally advanced or metastatic breast cancer confirmed by histology.
Patients previously received 1-2 lines of endocrine therapy.
Patients with rapid disease progress and investigators determine that endocrine therapy is not suitable or tolerant.
A history of severe clinical cardiovascular diseases.
Patients with uncontrollable tumor-related pain as judged by investigators.
Severe infection exists within 4 weeks before the first study administration.